Renovorx, Inc. (RNXT) Stock Price & Analysis

Renovorx, Inc. (RNXT) fell 7.74% to USD 2.21 as of September 8, 2026 at 15:31 UTC, according to Nexqual real-time market data.

RNXT last closed at USD 2.21; the session ranged USD 2.15–2.35 on volume of 658,159 shares. Market capitalization is —, with a 52-week range of USD 0.7–2.59 (NCM). Source: Nexqual, September 8, 2026 at 15:31 UTC.

Key Statistics (as of September 8, 2026 at 15:31 UTC)

Technical Analysis (RNXT)

Nexqual's technical model rates RNXT "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of September 8, 2026 at 15:31 UTC.

From Renovorx, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• In addition, we have obtained FDA clearance for our RenovoCath delivery system, which is subject to FDA medical device regulations, including the Quality System Regulation.
• We obtain our RenovoCath delivery system from a single source, which must be manufactured in accordance with the FDA Quality System Regulation (QSR).

Partnerships

• Our failure to achieve and maintain these high-quality manufacturing standards in collaboration with our third-party manufacturers, including the incidence of manufacturing errors, could result in patient injury or death, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could harm our business, financial condition and results of operations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 15:31 UTC. This page is informational and not investment advice.